Based on 98 hours of video footage and more than 1,200 data entries of current monovision contact lens, multifocal contact lens, and reading spectacles wearers, the analysis suggests that lifestyle and emotional connections to vision have a significant impact on the success of a presbyopia management plan. The authors recommend eye care professionals consider obtaining more patient input on those dimensions, with an empathetic approach offering the best opportunities to match individuals with correction types.
CooperVision MyDay® daily disposable multifocal contact lenses are an expansion of the popular premium silicone hydrogel 1-day family. Leveraging the company’s deep expertise in optical design and prescribing practices, the new lenses are the first to feature the Binocular Progressive System™, an innovative 3 add approach that caters to all levels of presbyopia with simplified fitting2, optimal visual acuity at all distances, and comfortable wear for exceptional performance.
“Spherical contact lens wearers live active, on-the-go lifestyles, but as they look to continue contact lens wear with their presbyopia3, they’re typically unable to experience the same clear vision. As a result, they often turn to reading glasses over their contact lenses or drop out of the category entirely. With so many factors to consider, presbyopes need a contact lens that checks all the boxes: excellent vision, comfort, and ocular health4,” said Michele Andrews, OD, Vice President of Professional and Government Affairs, CooperVision.
“MyDay® multifocals are ideal for all contact lens wearers with presbyopia5. It’s an inventive product that will help eye care professionals in most every practice setting, and we are enthusiastic about its potential to help grow the multifocal category.”
1 A Zucaro, A Deal, R O’Leary, P Lazon, G Orsborn, A Sulley. Ethnography research to understand the vision and switching experiences of living with presbyopia. Paper Presentation, BCLA 2021.
2 CVI data on file 2020. Prospective, double-masked, bilateral, one-week dispensing study UK with MyDay® daily disposable multifocal; n=104 habitual multifocal contact lens wearers; CVI data on file 2021. Prospective, subject-masked, randomized, bilateral, two-week dispensing study at 5 US sites with MyDay® daily disposable multifocal; n=58 habitual multifocal contact lens wearers.
3 Akerman D. 40 is the New 20/20 — Presbyopia Equals Opportunity. CL Spectrum, March 2010.
4 Data on file 2020. Kubic Online Survey with spherical soft contact lens wearers with presbyopia/symptoms. N= 1005 (555 1 Day, 450 FRP wearers). US, UK, JP; weighted equally.
5 CVI data on file 2020. Prospective, double-masked, bilateral, 1-week dispensing study with MyDay daily disposable multifocal; n=104 habitual MFCL wearers.
About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (“Cooper”) is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
